A. Horn

Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols

M. Schrappe, G. Henze, H. Müller, 2000, British journal of haematology.

Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

C. von Kalle, S. Willich, W. Lieb, 2021, Infection.

Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study

C. von Kalle, F. Tacke, Sebastian Albus, 2021, Clinical Microbiology and Infection.

PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols

M. Schrappe, G. Henze, H. Müller, 2002, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL‐BFM 95 reinduction treatment

M. Schrappe, H. Müller, R. Beier, 2001, British journal of haematology.

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

C. von Kalle, N. Suttorp, D. Treue, 2021, The Lancet Respiratory Medicine.